{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Global Health Status is calculated from two questions on the EORTC QLQ-C30. The question responses range from 1 \"very poor\" to 7 \"excellent\" such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best).","groups":[{"description":"\\[Intent-to-treat\\]\n\nSTEP 1 (all patients): Patients who received allowed neoadjuvant systemic therapy before study entry undergo pleurectomy/decortication (P/D) within 4 to 8 weeks of systemic therapy. Otherwise, patients undergo P/D within 4 weeks of study entry followed within 4 to 8 weeks by four 21-day cycles of pemetrexed and cisplatin or carboplatin on day 1.\n\nSTEP 2 (randomized): Patients receive no treatment.","id":"OG000","title":"Arm I (Step 1: Chemotherapy, P/D: Step 2: no Treatment)"},{"description":"\\[Intent-to-treat\\]\n\nSTEP 1 (all patients): Same as Arm 1.\n\nSTEP 2 (randomized): Within 4-8 weeks from the end of Step 1 treatment, patients undergo 25-28 fractions of intensity modulated radiation therapy (IMRT) or pencil beam scanning (PBS) proton therapy 5 days/week over 6 weeks.","id":"OG001","title":"Arm II (Step 1: Chemotherapy, P/D, Step 2: IMRT/PBS)"}],"populationDescription":"No patients had both baseline and 9-month data, therefore change from baseline could not be calculated for any patient.","reportingStatus":"POSTED","timeFrame":"Randomization and 9 months","title":"Change From Randomization to 9 Months in Global Heath Status (GHS) Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)","type":"SECONDARY"}